Trust Score calculated by AI analyzing study rigor, sample size (n), and the scientific source impact factor.
Citicoline 1000 mg/day improves 90‑day MMSE, Barthel Index, and GOS‑E scores in mild‑to‑moderate TBI patients
Summary
“Citicoline 1000 mg/day increased 90‑day MMSE, Barthel Index, and GOS‑E scores compared with placebo in mild‑to‑moderate traumatic brain injury.”
Adrian Castro created Biohacker Age to have a place to closely follow longevity and biological optimization research without relying on sensationalist headlines. Content is produced with AI assistance from scientific literature and is editorially reviewed before publishing.
About our methodology →The Finding
In a triple‑blind, randomized, placebo‑controlled pilot trial, Bavali Oleyayi and colleagues from the Department of Neurosurgery reported that 60 adults with mild‑to‑moderate traumatic brain injury who received citicoline 1000 mg/day for 90 days achieved a mean MMSE score of 25.2 ± 2.1, compared with 21.5 ± 3.4 in the placebo group (p < 0.001).
How They Got There
The study enrolled 60 participants, allocated 1:1 to citicoline or matched placebo. Primary and secondary outcomes were assessed at day 90.
| Outcome | Citicoline (n = 30) | Placebo (n = 30) | p‑value |
|---|---|---|---|
| Mini‑Mental State Examination (MMSE) | 25.2 ± 2.1 | 21.5 ± 3.4 | <0.001 |
| Barthel Index | 85.0 ± 0.5 | 70.0 ± 0.8 | <0.001 |
| Glasgow Outcome Scale‑Extended (GOS‑E) | 5.2 ± 1.3 | 3.6 ± 0.8 | <0.001 |
Safety monitoring recorded new or worsened intracerebral hemorrhage in two citicoline recipients versus three placebo recipients (p = 0.65).
The Mechanism: What Happens Biologically
Citicoline (CDP‑choline) serves as a precursor for phosphatidylcholine synthesis, supporting membrane repair after neuronal injury. It also enhances acetylcholine production, modulates glutamate excitotoxicity, and attenuates inflammatory cascades via reduced cytokine release. These actions converge on improved neuronal survival and synaptic plasticity, which can translate into better cognitive and functional recovery.
Study Limitations
- Sample size limited to 60 participants, reducing statistical power for subgroup analyses.
- Single‑center design may limit generalizability to broader trauma populations.
- Follow‑up restricted to 90 days; long‑term durability of benefits remains unknown.
Practical Application
It's too early to apply this to a personal protocol for healthy adults. The trial focused on patients with mild‑to‑moderate TBI, a specific clinical scenario. Translating the findings to performance optimization would require multicenter, adequately powered studies in non‑injured populations, dose‑response investigations, and comprehensive safety profiling.
Disclaimer: This article is for informational and educational purposes only. The information presented does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before modifying your diet, supplementation, or exercise routines. The scientific studies cited reflect the state of knowledge at their publication date and may be subject to revision.
Legal Notice
Medical Disclaimer: This content is for informational and educational purposes only. It is not intended to substitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or supplementation.
Science in your inbox
The most relevant studies of the week, curated and analyzed.
No spam. Unsubscribe anytime.